Leveraging JAK Inhibitors in Ulcerative Colitis: Strategies for the IBD Management Team

preview_player
Показать описание

This accredited, on-demand webcast features a presentation by Dr. Hans Herfarth on the use of JAK inhibitors for the treatment of ulcerative colitis.

© 2020 NACCME, an HMP Company
  1. HMP Education
  2. CME
  3. Continuing Medical Education
  4. Education
  5. Accreditation
  6. Medical
Рекомендации по теме
Leveraging JAK Inhibitors 0:20:57

Leveraging JAK Inhibitors in Ulcerative Colitis: Strategies for the IBD Management Team

JAK inhibitors for 0:26:43

JAK inhibitors for IBD

Novel JAK Inhibitors 0:22:00

Novel JAK Inhibitors Under Investigation for IBD

IBD Clinical Update: 0:12:48

IBD Clinical Update: New and Emerging Targeted Therapies

Novel Targets and 0:15:09

Novel Targets and Therapeutic Perspectives in IBD: Beyond Anti-TNF

JAK Therapies: Mechanism 0:15:28

JAK Therapies: Mechanism of Action, Pharmacotherapeutic Profiles, and Positioning

The Evolving Therapeutic 0:49:17

The Evolving Therapeutic Paradigm in IBD: Optimal Positioning of New and Emerging Agents

Newer therapies on 0:23:14

Newer therapies on the horizon for Inflammtory Bowel Disease

The Expanding Role 0:36:51

The Expanding Role of JAK Inhibitors Across IMIDs

Improvements in Targeted 0:45:53

Improvements in Targeted IBD Management: Innovative Biologics and Small Molecules

June IBD Club 0:05:50

June IBD Club | Tofacitinib for severe ulcerative colitis

Understanding the use 0:22:05

Understanding the use of IL12/IL23 targeted biologics

Tofacitinib as induction 0:04:35

Tofacitinib as induction and mantainance of ulcerative colitis

Right Treatment for 0:22:02

Right Treatment for the Right Patient at the Right Time Prof. R.Panaccione during the IBD PRACTICE

Inflammatory Bowel Disease 0:02:19

Inflammatory Bowel Disease – Pathophysiology and JAK/STAT Signaling

The Causes and 0:25:11

The Causes and Consequences of IBD

Treatment of Ulcerative 0:09:56

Treatment of Ulcerative colitis

Biologic Medications for 0:01:12

Biologic Medications for IBD

Patient Outcomes With 0:05:22

Patient Outcomes With Early vs Late Use of Vedolizumab in Ulcerative Colitis

What future therapies 0:17:11

What future therapies need to be developed for our IBD patients?

Serious Infection Risk 0:08:00

Serious Infection Risk from the Filgotinib Drug Development Program: Dr. James Galloway

Overview of Novel 0:05:03

Overview of Novel Therapeutic Approaches to IBD

Treat-to-Target in IBD: 0:10:50

Treat-to-Target in IBD: Decreasing Inflammation & Achieving Mucosal Healing

Discussing Rheumatology: Safety 0:08:15

Discussing Rheumatology: Safety of filgotinib, and tofacitinib in pJIA